⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14911168 | 0.75 | — | — | |
| SCHEMBL7220284 | 0.71 | — | — | |
| SCHEMBL358262 | 0.71 | — | — | |
| SCHEMBL7228353 | 0.71 | — | — | |
| Water SCHEMBL28236237 | 0.68 | NPC1 (0.50) | — | |
| SCHEMBL17065171 | 0.68 | ALOX15 (0.34) | — | |
| SCHEMBL1904067 | 0.68 | L3MBTL1 (0.47) | — | |
| SCHEMBL8318736 | 0.67 | — | — | |
| SCHEMBL6995839 | 0.67 | ADH1B (0.34) | — | |
| SCHEMBL16446647 | 0.67 | TRPM8 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229909-B1 | BINDING MEMBERS FOR HUMAN C-MAF | INBIOMOTION SL (ES) | 2020-10-14 | — | — | EP | disclosed |
| EP-3458610-A1 | THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS | Inbiomotion S.L. (ES) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017203468-A1 | THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS | INBIOMOTION S.L. (ES) | 2017-11-30 | — | — | WO | disclosed |
| EP-3229909-A1 | BINDING MEMBERS FOR HUMAN C-MAF | Inbiomotion S.L. (ES) | 2017-10-18 | — | — | EP | disclosed |
| EP-3055429-A2 | METHOD FOR THE PROGNOSIS AND TREATMENT OF METASTASIZING CANCER OF THE BONE ORIGINATING FROM BREAST CANCER | Fundació Institut de Recerca Biomèdica (IRB Barcelona) (ES) | 2016-08-17 | — | — | EP | disclosed |
| WO-2016092524-A1 | BINDING MEMBERS FOR HUMAN C-MAF | INBIOMOTION S.L. (ES) | 2016-06-16 | — | — | WO | disclosed |
| EP-2971113-A2 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | Fundació Institut de Recerca Biomèdica (IRB Barcelona) (ES) | 2016-01-20 | — | — | EP | disclosed |
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| WO-2015052583-A2 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES) | 2015-04-16 | — | — | WO | disclosed |
| EP-2836837-A2 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | Fundació Institut de Recerca Biomèdica (IRB Barcelona) (ES) | 2015-02-18 | — | — | EP | disclosed |
| WO-2014184679-A2 | METHOD FOR THE PROGNOSIS AND TREATMENT OF RENAL CELL CARCINOMA METASTASIS | INBIOMOTION S.L. (ES) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014140933-A2 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO PRIVADA INSTITUT DE RECERCA BIOMEDICA (ES) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013153458-A2 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | INBIOMOTION S.L. (ES) | 2013-10-17 | — | — | WO | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| EP-2601185-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012016993-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-09 | — | — | WO | disclosed |
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |